PHARMAC medical director
Dr John Wyeth has defended
New Zealand’s Pharmaceutical
Management Agency (PHARMAC)
position rejecting drugs that are
now being funded in Australia.
“Most of the additional medicines
funded in Australia but not in New
Zealand don’t offer health gains
that would be considered clinically
meaningful by international cancer
specialists in recent research,” he
said.
“Using these measures of survival,
New Zealand’s usual standards
of care offer better health gains
for people than the medicines on
offer.”
To fund all of the medicines
currently available in Australia but
not New Zealand would cost the
country an additional $80 million
per year, said Wyeth.
Since the analysis was completed,
New Zealand has funded one more
cancer medicine, while Australia
has funded five, PHARMAC reports.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.